Citalopram in the treatment of obsessive-compulsive disorder: An open pilot study

Acta Psychiatrica Scandinavica

Volumn 96, Issue 5, 1997, Pages 343-346

  Koponen, H ^a,c   Lepola, U ^b,c   Leinonen, E ^d,e   Jokinen, R ^f   Penttinen, J ^f   Turtonen, J ^f  

^a Moisio Hospital   (Finland)

^b Psychiatric Research Clinic of Kuopio   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d Pitkäniemi Hospital   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f Turku Psychiatric Clinic   (Finland)

Author keywords

Anxiety disorders; Citalopram; Obsessive compulsive disorder

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPULSION; DREAMING; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MALE; NAUSEA; OBSESSION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0030724916     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1997.tb09927.x     Document Type: Article

References (22)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
2. KARNO M, GOLDING J, SORENSON S, BURNAM A. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988: 45: 1094-1099.
3. GEORGE MS. Obsessive-compulsive disorder. Int Clin Psychopharmacology 1991: 6 (Suppl. 3): 57-68.
4. ZOHAR J, MUELLER EA, INSEL TR, ZOHAR-KADOUCH RC, MURPHY DL. Serotonergic responsivity in obsessive-compulsive disorder. Arch Gen Psychiatry 1987: 44: 946-951.
5. FLAMENT MF, RAPOPORT JL, MURPHY DL, BERG CJ, LAKE CR. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 1987: 44: 219-225.
6. PERSE TL, GREIST JH, JEFFERSON JW, ROSENFELD R, DAR R. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 1987: 144: 1543-1548.
7. PIGOTT TA, PATO MT, BERNSTEIN SE et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990: 47: 926-932.
8. GREIST J, CHOUINARD G, DUBOFF E et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995: 52: 289-295.
9. DUNBAR G, STEINER M, BUSHNELL WD, GERGEL I, WHEADON DE. Long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Eighth Congress of the European College of Neuropsychopharmacology. Eur Neuropsychopharmacology 1995: 5: 372.
10. HYTTEL J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressive activity. Prog Neuropsychopharmacol Biol Psychiatry 1982: 6: 277-295.
11. LEPOLA U, LEINONEN E, TURTONEN J, PENTTINEN J. The effects of citalopram in panic disorder and agoraphobia. A pilot study. Nord J Psychiatry 1993: 48: 13-17.
12. KOPONEN H, LEPOLA U, LEINONEN E. Citalopram in the treatment of obsessive-compulsive disorder. A report of two cases. Eur Psychiatry 1995: 10: 209-210.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, revised 3rd edn. Washington, DC: American Psychiatric Association, 1987.
14. MONTGOMERY SA, ÅSBERG MA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979: 134: 382-389.
15. GOODMAN WK, PRICE LH, RASMUSSEN SA et al. The Yale-Brown Obsessive-Compulsive Scale: development, use and reliability. Arch Gen Psychiatry 1989: 46: 1006-1011.
16. GUY W. ECDEU assessment manual for psychopharmacology revised. US Department of Health, Education and Welfare Publication (ADM) 76: 338. Rockville, MD: National Institute of Mental Health, 1976.
17. BECH P. Rating scales for psychopathology, health status and quality of life. Berlin: Springer, 1993.
18. LINGJÆRDE O, AHLFORS UG, BECH P, DENCKER SJ, ELGEN K. The UKU side-effect rating scale. Acta Psychiatr Scand 1987: 76 (Suppl. 334): 1-100.
19. BAXTER LR, SCHWARTZ JM, MAZZIOTA JC et al. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 1988: 145: 1560-1563.
20. HAY P, SACHDEV P, CUMMING S et al. Treatment of obsessive-compulsive disorder by psychosurgery. Acta Psychiatr Scand 1993: 87: 197-207.
21. PATO MT, ZOHAR-KADOUCH R, ZOHAR J, MURPHY DL. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988: 145: 1521-1525.
22. SCHNEIER FR, KLEIN DF. Placebo response in anxiety disorders. Anxiety Disorders Association of America 16th Conference, Orlando, 1996.